Haplo-identical/Mismatched Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01793675

Enrollment

116

Registered

2013-02-15

Start date

2003-04-30

Completion date

2014-12-31

Last updated

2015-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced MDS Without Identical Sibling Donor

Brief summary

Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS), especially for advanced MDS (blast \>5%). However, many patients cannot find an HLA-matched donor. haploidentical donor is an alternative stem cell source. the study hypothesis: Haploidentical/mismatched hematopoietic stem cell transplantation can improve the survival of patients with myelodysplastic syndrome

Interventions

PROCEDUREtransplant with haploidentical donor

patients with advanced MDS without identical sibling donor receive haploidentical transplant

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Patients with MDS (1)intermediate-2 or high risk (2)low or intermediate-1 risk with drug resistance or disease progression * without identical sibling donor

Exclusion criteria

* Contraindication to HSCT * Pregnancy * Mental illness

Design outcomes

Primary

Measure	Time frame	Description
survival rate	participants will be followed for an expected average of one year	number of participants with survival at one year

Secondary

Measure	Time frame	Description
incidence of non-relapse mortality	one year	number of participants with non-relapse mortality at one year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 7, 2026